DOCSLIB.ORG

Catalogue Eng 1 1.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Catalogue Eng 1 1.Pdf GMP LIST OF CONTENTS: InfusIon therapy antIseptIcs and IrrIgatIon soLutIons RHEOSORBILACT® 8 LATREN® 8 DECASAN® 17 SODa-BUFER® 9 CYTOCLIN® 17 XYLAT® 9 TURUSOL® 18 TIVORTIN® 10 HOROSTEN® 18 GiK® 10 GECOTON® 11 GECODES® 11 SORBILACT® 12 AmINOCAPRONIC ACID, sol. 5% 12 antIBacterIaL and FAMOZOL® 13 fungIcIdaL drugs SUFER® 13 LEFLOCIN® 19 LEFLOCIN® 750 19 sIMpLeX InfusIon BIGAFLON® 20 soLutIons OFLOXACIN 20 MAXICIN® 21 SODIUM CHLORIDE sol. 0,9% 14 LINELID® 21 WATER FOR INJECTION 14 ORNIGIL® 22 GLUCOSE sol. 5% 14 CIPROFLOXACIN 22 POTASSIUM CHLORIDE 14 SOLUSEPTOL® 23 RINGER'S sol. 15 METRONIDAZOLE 23 RINGER's-laCTATE sol. 15 FLUCONAZOLE 24 SODIUM hyDROCARBONATE sol. 4% 15 FLUCONAZOLE 400 mg 24 MANNIT, 15% 16 POLygLUCIN 16 RHEOPOLygLUCIN 16 2 cartILage ModIfyIng anaLgesIcs and accessorIes for drugs anaesthetIcs InfusIon therapy HYALUAL®-aRTRO 25 LONGOCAIN® 30 SOLUVEN® 35 LONGOCAIN® HEAVY 30 SyrINGES WITH TWO NEEDLES 36 NOVOCAINE, sol. 0,25%, 0,5% 30 I.V. SETS (PS AND PB) 36 INFULGAN® 31 oraL soLutIons coMpressor LACTUVIT® 26 TIVORTIN® ASPARTATE 27 neBuLIZers «uLaIZer» ULAIZER® Pro 37 cLInIcaL nutrItIon ULAIZER® Home 37 ULAIZER® First Aid 37 AmINOL® 32 GLUXYL® 32 antI-tuBercuLosIs drugs MedICATIons for neBuLIZer therapy ISONIAZID syrup 28 antIVIraL drugs DECASAN® 38 RIFONAT 28 ® SODIUM CHLORIDE 38 INBUTOL® 29 NEBUTAMOL® 38 PASKONAT® 29 АКК® 33 NEBUFLUZON® 38 BITUB® 29 dIaLysIs soLutIons drugs for treatMent of wounds and uLcers DIAVITEC® PD 34 LACERTA® 39 3 "YURiA-PHARM" – a dynamically The total headcount of "YURiA-PHARM" is constantly growing growing company and at the moment, it exceeds 1000, 2/3 of them being involved in production and R&D. Founded in 1998, "YURiA-PHARM" focused its efforts towards the production of infusions and as of today, "YURiA-PHARM" is the leading infusion manufacturer not only in Ukraine, but "YURiA-PHARM" – a wide range of popular also in CIS. We supply medical facilities with more than 100 original and generic infusion preparations items of blood- and plasma substitute solutions, original Our company produces a number of medications (original infusion drugs, antibiotics, fungicidal drugs, syrups, antiseptics, and generic), which are not produced in CIS countries – parenteral nourishment medications, anti-tuberculosis drugs, RHEOSORBILACT®, SORBILACT®, DECASAN®, HOROSTEN® etc. syringes and I.V. sets. Our product line sums up to more For instance, RHEOSORBILACT® (30% of the total distribution than 40 infusions, completely covering the needs of medical of the medications included in B 05 ATC code (B05 - Blood facilities with infusion therapy medications. The annual substitutes and perfusion solutions) and SORBILACT® turnover of our company exceeds 60 mln bottles. constitute the basis of infusion therapy in Ukraine. They have completely replaced polyvinylpyrrolidone medications (such "YURiA-PHARM" confidently takes a as Hemodez, Neohemodez etc.) prohibited in many European leading position in the export markets and other countries, and dextran solutions, whose usage is We deliver our products to Russia, Moldova, Kazakhstan, restricted. Uzbekistan, Azerbaijan, Tajikistan, Kirgizia, Turkmenistan and In our portfolio we also have unique cosmetic therapeutic Georgia. More than 100 items are now being registered for products – HYALUAL® (an anti-age therapy, helps keep the usage in different countries and the number is continuously skin young and healthy for a long time), cartilage modifying growing. injectable drug – HYALUAL®-ARTRO – a unique innovative In 2008, "YURiA-PHARM" Corporation has received a Certificate cartilage protective medication of a new generation. It is of compliance to international quality management standards an effective combination of hyaluronic acid and sodium ISO 9001 (9001:2009). In 2011 "YURiA-PHARM" Corporation succinate for the treatment of osteoarthritis. was GMP certified. 4 "YURiA-PHARM" – appreciated by the At the moment our products are released in 9 forms, including physitians and the scientific medical prefilled syringes, nebules, bags for irrigation solutions, community polypropylene bags, PVC bags, glass bottles and plastic bottles. We cooperate intensively with many research institutions in "YURiA-PHARM" – a right hand of any the field. For the first time in CIS, in collaboration with the physician Hematologic Pathology and Transfusion Medical Institute of Ukraine's Academy of Medical Science, we have developed Our medications accelerate the patients' recovery due to their a group of complex multifunctional infusion solutions – higher efficiency, considerable decrease of complications RHEOSORBILACT®, SORBILACT® and XYLAT®, which today and minimal side-effects. Numerous reputable medical represent the basis of a new domain in internal medicine– investigations have proven a visible time saving factor in Restricted-volume infusion therapy. Our corporation inpatient treatment as well as a higher therapeutic comfort conducts an intensive researches with new medications as level. These factors reduce treatment cost and increase the well as examines more deeply the capacity of the existing average annual bed turnover. ones. We make large investments in Research & Development to help prove the quality and efficiency of our medications "YURiA-PHARM" – a reliable and according to the requirements of the “case-based medicine”. advantageous partner "YURiA-PHARM" – constant improvement According to a broad experience, the practical usage of of production according to market medications manufactired by "YURiA-PHARM" have in general, requirements enhanced the overall image of both medical facilities and Keeping in mind the constant enhancing of quality and physicians. accessibility of treatment, we improve the forms and dosages of the medications on a permanent basis. Uncompromising quality and reasonable pricing have made our medications the bestsellers in Ukraine and in the CIS and we have every reason to expect similar success in other countries. 5 "YURiA-PHARM" Facts: • leader in the production of infusion solutions; • more than 40% annual growth rate; • more than 100 items in the product line; • total headcount (employees) exceed 1000; • annual turnover up to 60 million units; • exports to 17 countries; • 80% of annual net profit is invested in the modernization of production; • each year about 10-15 new medical products are released each year; • presence of an operational quality control system ISO 9001: 2009; • GMP-certified manufacturer. 6 "YURiA-PHARM" Corporate philosophy OUR PURPOSE OUR VISION Life is the greatest value of all! We are a leading specialized pharmaceutical corporation, Our calling is to preserve and improve it! and the best employer in the market. OUR MISSION OUR VALUES • We create unique solution for health care and treatment. • The trust of our Partners • We earn the respect of our Community, recognition of our • We are an ambitious team of professionals united by our Doctors and the trust of our Patients. corporate spirit • We engage the creative potential of our Employees and • Supreme product quality Partner and increase their welfare. • Superior level of Client interaction • Our innovations shape the style of the pharmaceutical • Effective internal communication business. • Maximum performance and high profitability • Self-actualization of each Employee 7 InfusIon therapy RHEOSORBILACT® LATREN® Number One Enhanced infusion therapy drug microcirculatory effect Ukraine’s research heritage 2009 How supplied: How supplied: 200 ml and 400 ml glass bottles 100 ml and 200ml glass bottles RHEOSORBILACT® is a polyfunctional electrolytic balance correction, mild metabolic LATREN® is an infusion solution with a balanced hyperosmolar drug. The rational combination acidosis correction and hepatoprotective isoosmolar electrolyte solution (Ringer's lactate of components that complement and action. RHEOSORBILACT® is the foundation of solution) which potentiates the effect of potentiate each other, allowing the Restricted-volume infusion therapy, a modern pentoxifylline. Effective for both peripheral and achievement of a polyfunctional effect: branch of internal medicine. brain circulatory disorders. hemodynamics stabilization, pronounced LATREN® is supplied as a final dosage form, detoxication effect, improved microcirculation therefore eliminating the risk of technical error or and blood rheological properties, hydro- solution infection. 8 InfusIon therapy SODA-BUFER® XYLAT® Buffered Infusion therapy sodium for diabetes hydrocarbonate mellitus and solution ketosis of different genesis How supplied: How supplied: 100 ml, 200 ml and 20 ml glass bottles 200 ml and 400 ml glass bottles The use of SODA-BUFER® is This ensures the exceptional safety A multicomponent hyperosmolar solution pronounced antiketogenic action. recommended for diseases of this drug. containing xylytol, sodium acetate and Sodium acetate is a slow-acting and pathological conditions The use of SODA-BUFER® of 20 a balanced electrolyte complex. It has alkalizing agent that ensures acidosis accompanied with metabolic ml is recomended for correcting antiketogenic, nitrogenpreserving and correction without sharp pH level acidosis. Unlike regular baking soda the pH of acid infusion solutions, lipotropic effects. Xylytol is a pentabasic fluctuations. Due to the balanced (4.2% sodium carbonate) with a pH thus making an angioprotective alcohol with insulinindependent utilization electrolyte complex, the drug ensures of 8.3-11.0, SODA-BUFER®, due to effect as well as minimizing that does not influence the blood
Load more

Recommended publications
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Irish Medicines Board
    Irish Medicines Board IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. No.540 of 2007) PA0167/098/001 Case No: 2063572 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to Baxter Healthcare Limited Caxton Way , Thetford , Norfolk IP24 3SE , United Kingdom an authorisation, subject to the provisions of the said Regulations, in respect of the product CLINIMIX N9G15E, solution for infusion The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 19/05/2009 until 11/12/2009 . Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. ______________________________________________________________________________________________________________________ Date Printed 19/05/2009 CRN 2063572 page number: 1 Irish Medicines Board Part II Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT CLINIMIX ® N9G15E, solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION CLINIMIX ® N9G15E is packaged in a dual compartment plastic bag containing respectively an amino acid solution with electrolytes and a glucose solution with calcium. The injectable amino acid solution contains 15 L -amino acids
    [Show full text]
  • Development of the Medicines Optimisation Assessment Tool (MOAT)
    Department of Practice and Policy UCL School of Pharmacy PhD Thesis – University College London Development of the Medicines Optimisation Assessment Tool (MOAT) Targeting hospital pharmacists' input to reduce risks and improve patient outcomes Cathy Anne Geeson NIHR Clinical Doctoral Research Fellow Pharmacy Department Luton and Dunstable University Hospital 1 Declaration I, Cathy Geeson confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Signature: Date: 2 Abstract Abstract Background Medicines optimisation is a key role for hospital pharmacists, but with ever-increasing demands on services, there is a need to increase efficiency while maintaining patient safety. The aim of this study was to use prognostic modelling to develop a prediction tool, the Medicines Optimisation Assessment Tool (MOATTM), to target patients most in need of pharmacists’ input while in hospital. Methods and analysis Patients from adult medical wards at two UK hospitals were prospectively included into this cohort study between April and November 2016. Data on medication related problems (MRPs) were collected by pharmacists at the study sites as part of their routine daily clinical assessment of patients. Data on potential risk factors, such as polypharmacy and use of ‘high-risk’ medicines, were collected retrospectively from the information departments at the study sites, laboratory reporting systems and patient medical records. Multivariable logistic regression was used to determine the relationship between potential risk factors and the study outcome, namely preventable MRPs that were at least moderate in severity. A simplified electronic scoring system (the MOAT) was then developed.
    [Show full text]
  • Pileptic Fosphenytoin
    PACKAGE LEAFLET: INFORMATION FOR THE PATIENT TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion Read all of this leaflet carefully before you will be administered this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or nurse. • If you get any side effect, talk to your doctor or nurse. This includes any side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is and what it is used for 2. What you need to know before TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is administered 3. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion will be used 4. Possible side effects 5. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is stored 6. Contents of the pack and other information 1. What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is and what it is used for TRIOMEL is an emulsion for infusion. It is presented in a bag with 3 chambers. One chamber contains a glucose solution, the second one contains a lipid emulsion and the third one contains an amino acid solution. TRIOMEL is used to provide nutrition to adults and children greater than 2 years of age by a tube into a vein when normal feeding by mouth is not suitable. TRIOMEL must only be used under medical supervision.
    [Show full text]
  • Summary of Product Characteristics 1. Name Of
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Numeta G19E emulsion for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION This medicinal product is presented in the form of a three chamber bag. Each bag contains a sterile non-pyrogenic combination of a glucose solution, a paediatric amino acids solution, with electrolytes, and a lipid emulsion, as described below. Container size 50% glucose solution 5.9% amino acids solution 12.5% lipid emulsion with electrolytes 1000 mL 383 mL 392 mL 225 mL If lipid administration is undesirable, the design of the bag allows the possibility to activate only the peel seal between the amino acids/electrolytes and glucose chambers, leaving the peel seal between the amino acids and lipid chambers intact. The content of the bag can subsequently be infused with or without lipids. The composition of the drug product after mixing of the two (amino acids and glucose 2 chamber bag, 775 mL solution) or three (amino acids, glucose and lipid 3 chamber bag, 1000 mL emulsion) chambers are provided in the following table. Page 1 of 28 Composition Active Substance Activated 2CB Activated 3CB (775 mL) (1000 mL) Amino Acid Chamber Alanine 1.83 g 1.83 g Arginine 1.92 g 1.92 g Aspartic acid 1.37 g 1.37 g Cysteine 0.43 g 0.43 g Glutamic acid 2.29 g 2.29 g Glycine 0.91 g 0.91 g Histidine 0.87 g 0.87 g Isoleucine 1.53 g 1.53 g Leucine 2.29 g 2.29 g Lysine monohydrate 2.82 g 2.82 g (equivalent to Lysine) (2.51 g) (2.51 g) Methionine 0.55 g 0.55 g Ornithine hydrochloride 0.73 g 0.73 g (equivalent to Ornithine)
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • European Medicines Agency Referrals Categorised by Type of Referral Procedure and Date Supplementary Tabl
    Supplementary material BMJ Open Supplementary Table 1: European Medicines Agency referrals categorised by type of referral procedure and date Referral category Frequency by CHMP/CMDha opinion date Total 2013 2014 2015 2016 2017 Jan-Jun Article 107i procedures 5 1 0 0 0 6 Article 20 procedures 2 3 1 4 1 11 Article 31 referrals 13 13 5 3 1 35 Total 20 17 6 7 2 52 a) Committee for Medicinal Products for Human Use/Coordination Group for Mutual Recognition and Decentralised Procedures – Human Supplementary Table 2: ATCa therapeutic subgroup of medicinal product by frequency for the 52 included referrals ATC Subgroup definition No. of subgroup referrals code G03 Sex hormones and modulators of the genital system 6 N02 Analgesics 6 A10 Drugs used in diabetes 3 C01 Cardiac therapy 3 M01 Anti-inflammatory and antirheumatic products 3 None Not applicable/available 3 R05 Cough and cold preparations 3 A03 Drugs for functional gastrointestinal disorders 2 B05 Blood substitutes and perfusion solutions 2 C04 Peripheral vasodilators 2 C10 Lipid modifying agents 2 G02 Other gynelogicals 2 L01 Antineoplastic agents 2 M03 Muscle relaxants 2 N05 Psycholeptics 2 R03 Drugs for obstructive airway diseases 2 B01 Antithrombotic agents 1 B02 Antihemorrhagics 1 B03 Antianemic preparations 1 C08 Calcium channel blockers 1 C09 Agents acting on the renin-angiotensin system 1 J01 Antibacterials for systemic use 1 J02 Antimycotics for systemic use 1 J05 Antivirals for systemic use 1 L04 Immunosuppresants 1 M05 Drugs for treatment of bone diseases 1 N03 Antiepileptics 1 N07 Psychoanaleptics 1 R02 Throat preparations 1 R07 Other respiratory system products 1 a) Anatomical Therapeutic Chemical (ATC) Classification System Brown JP, et al.
    [Show full text]
  • PERIOLIMEL N4E, Emulsion for Infusion
    Olimel/Periolimel - FR/H/0419/001-006/MR Page 1 of 32 Proposed common SmPC consolidated March 2013 PERIOLIMEL N4E, emulsion for infusion OLIMEL N5E, emulsion for infusion OLIMEL N7E, emulsion for infusion OLIMEL N9E, emulsion for infusion OLIMEL N7, emulsion for infusion OLIMEL N9, emulsion for infusion SUMMARY OF PRODUCT CHARACTERISTICS (SmPC) English master Proposed version – March 2013 Annotated version In order to facilitate the review, this document consists in a combined SmPC for all strenghts. This annotated version includes all revised wording clearly identified using track-changes mode with the following annotations: - Grey-shaded titles the strength in which alternative text elements refer. Grey-shaded text is used to highlight text which will not be included in each separated SPC. - Information to be filled in is presented using the following bracket {text}. - Text to be selected or deleted as appropriate is presented using the following bracket <text>. Confidential Document Olimel/Periolimel - FR/H/0419/001-006/MR Page 2 of 32 Proposed common SmPC consolidated March 2013 1. NAME OF THE MEDICINAL PRODUCT <PERIOLIMEL N4E, emulsion for infusion OLIMEL N5E, emulsion for infusion OLIMEL N7E, emulsion for infusion OLIMEL N9E, emulsion for infusion OLIMEL N7, emulsion for infusion OLIMEL N9, emulsion for infusion> 2. QUALITATIVE AND QUANTITATIVE COMPOSITION <PERIOLIMEL / OLIMEL> is presented in the form of a 3-compartment bag. For PERIOLIMEL N4E, OLIMEL N5E, OLIMEL N7E and OLIMEL N9E: <Each bag contains a glucose solution with calcium,
    [Show full text]
  • Summary of Product Characteristics
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT CLINIMIX N9G15E, solution for infusion CLINIMIX N9G20E, solution for infusion CLINIMIX N12G20, solution for infusion CLINIMIX N12G20E, solution for infusion CLINIMIX N14G30, solution for infusion CLINIMIX N14G30E, solution for infusion CLINIMIX N17G35, solution for infusion CLINIMIX N17G35E, solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION CLINIMIX [N9G15E] [N9G20E] [N12G20] [N12G20E] [N14G30] [N14G30E] [N17G35] [N17G35E] is packaged in a dual compartment plastic bag containing respectively an amino acid solution [For Clinimix formulations without electrolytes: without electrolytes] [For Clinimix formulations with electrolytes: with electrolytes] and a glucose solution [For Clinimix formulations without electrolytes: without calcium] [For Clinimix formulations with electrolytes: with calcium]. The injectable amino acid solution contains 15 L-amino acids (8 essential amino acids) needed for the protein synthesis. The amino acid profile is the following: - Essential amino acids/Total amino acids = 41.3 % - Essential amino acids/Total nitrogen = 2.83 - Branched chain amino acids/Total amino acids = 19 % The quantitative composition of CLINIMIX [N9G15E] [N9G20E] [N12G20] [N12G20E] [N14G30] [N14G30E] [N17G35] [N17G35E] is the following: [For Clinimix N9G15E] 5.5% Amino acid solution with 15% Glucose solution with calcium electrolytes Active ingredients L-Leucine 4.02 g/l L-Phenylalanine 3.08 g/l L-Methionine 2.20 g/l L-Lysine 3.19 g/l (as L-Lysine hydrochloride)
    [Show full text]
  • Estonian Statistics on Medicines 2014
    Estonian Statistics on Medicines 2014 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 153,9425 A01 STOMATOLOGICAL PREPARATIONS 0,0769 A01A STOMATOLOGICAL PREPARATIONS 0,0769 A01AB Antiinfectives and antiseptics for local oral treatment 0,0769 A01AB09 Miconazole(O) 7361,6 g 0,2 g 0,0769 A01AB12 Hexetidine(O) 2482960 ml A01AB81 Neomycin + Benzocaine(C) 24400 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone + Thymol(dental) 3081 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine + Cetylpyridinium chloride(gingival) 189390 g A01AD81 Lidocaine + Cetrimide(O) 24760 g A01AD82 Choline salicylate(O) 878880 pieces A01AD83 Lidocaine + Chamomille extract(O) 331510 g A01AD86 Lidocaine + Eugenol(gingival) 600 g A01AD90 Lidocaine + Paraformaldehyde(dental) 45 g A02 DRUGS FOR ACID RELATED DISORDERS 39,9050 A02A ANTACIDS 1,0057 A02AD Combinations and complexes of aluminium, calcium and magnesium compounds 1,0057 A02AD81 Aluminium hydroxide + Magnesium hydroxide(O) 615400 pieces 10 pieces 0,1285 A02AD81 Aluminium hydroxide + Magnesium hydroxide(O) 2824956 ml 50 ml 0,1180 A02AD82 Aluminium aminoacetate + Magnesium oxide(O) 398580 pieces 10 pieces 0,0832 A02AD83 Calcium carbonate + Magnesium carbonate(O) 3237240 pieces 10 pieces 0,6760 A02AF Antacids with antiflatulents A02AF80 Aluminium hydroxide + Magnesium hydroxide + Simeticone(O) 96560 ml DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE A02B 38,8993 (GORD) A02BA H2-receptor antagonists
    [Show full text]
  • Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
    LEGEMIDDELSTATISTIKK 2019:2 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Christian Lie Berg Kristine Olsen Solveig Sakshaug Utgitt av Folkehelseinstituttet / Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2019 Tittel/Title: Legemiddelstatistikk 2019:2 Reseptregisteret 2014–2018 / The Norwegian Prescription Database 2014–2018 Forfattere/Authors: Christian Berg, redaktør/editor Kristine Olsen Solveig Sakshaug Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no / The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon / Contact information: Folkehelseinstituttet / Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8406-014-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2014–2018 [The Norwegian Prescription Database 2014–2018] Legemiddelstatistikk 2019:2, Oslo, Norge: Folkehelseinstituttet, 2019. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian
    [Show full text]